A-3556. Mini Lecture
Session: Slide Session: Human Pharmacodynamics of Effect and Toxicity
Monday, October 27, 2008: 12:00 AM
Room: Constitution B (Grand Hyatt)
Thomas Lodise, PharmD, Albany College of Pharmacy, Albany, NY and  T. P. Lodise,
Cubist Role(s): Consultant, Grant Investigator, Speaker's Bureau, Consultant, Grant Investigator, Speaker's Bureau, Consultant, Grant Investigator, Speaker's Bureau, Consultant, Grant Investigator, Speaker's Bureau, Received: Research Grant, Speaker Honorarium, Consulting Fee.
Pfizer Role(s): Grant Investigator, Speaker's Bureau, Grant Investigator, Speaker's Bureau, Grant Investigator, Speaker's Bureau, Grant Investigator, Speaker's Bureau, Received: Research Grant, Speaker Honorarium, Consulting Fee.
Astra-Zeneca Role(s): Speaker's Bureau, Speaker's Bureau, Speaker's Bureau, Speaker's Bureau, Received: Speaker Honorarium.
Ortho-McNeil Role(s): Consultant, Consultant, Consultant, Consultant, Received: Consulting Fee.
Taganta Role(s): Consultant, Consultant, Consultant, Consultant, Received: Consulting Fee.

Dr. Thomas Lodise is an Associate Professor at Albany College of Pharmacy, Albany, New York. Dr. Lodise, a 1999 Summa Cum Laude Doctor of Pharmacy graduate of Temple University School of Pharmacy, joined the faculty at Albany College of Pharmacy in August 2002. Prior to Albany College of Pharmacy, he completed the APhA-ASHP accredited Pharmacy Practice Residency at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania in 2000 and the Infectious Diseases Pharmacotherapy and Outcomes Fellowship at Wayne State University, Detroit, Michigan in 2002.
Integrating his dual interests in research and patient care, his current research focuses on the epidemiology and outcomes of bacterial infections, and his work explores the antibiotic exposure-response relationship among patients. His specific objectives are threefold: develop patient care strategies and antibiotic regimens that improve outcomes, reduce the likelihood of toxicity, and minimize the emergence of antibiotic resistance.
Dr. Lodise is currently implementing epidemiologic and outcomes research proposals at both the Albany Medical Center and Stratton VA Medical Center. He also collaborates extensively with the Ordway Research Institute. He has received funding from both pharmaceutical industry and competitive grant sources for many of his proposals. To date, he has published over 30 peer-reviewed articles in reputable scientific journals, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Chest and Journal of Antimicrobial Chemotherapy.
His clinical practice site is the Stratton VA Medical Center, where he coordinates the antibiotic monitoring service. He is a member of the antibiotic subcommittee at the Albany Medical Center Hospital and is a Visiting Professor at Ordway Research Institute. He is also enrolled in the Ph.D. program in Epidemiology at the State University of New York School of Public Health, Albany, New York.
On a national level, Dr. Lodise is a member of the Society of Infectious Diseases Pharmacists (SIDP), the American Association of Colleges of Pharmacy (AACP) and American College of Clinical Pharmacist (ACCP). On the state level, he is president for the New York ACCP chapter. He also serves as a reviewer for numerous medical and pharmacy journals.